Today: 10 June 2026
Browse Category

Rocket Lab 9 January 2026 - 26 January 2026

Rocket Lab stock price slides as Neutron tank rupture clouds 2026 launch plans

Rocket Lab stock price slides as Neutron tank rupture clouds 2026 launch plans

Rocket Lab shares fell 6.6% to $83.06 by midday Monday after a first-stage tank ruptured during Neutron rocket testing. The company is reviewing test data and will update its launch schedule during its February earnings call. Shares remain up 26% year-to-date despite the setback. Investors are watching for delays to Neutron’s debut, originally targeted for early 2026.
26 January 2026
····
Rocket Lab stock price today: RKLB slips after hours as Neutron tank test rupture keeps timeline in focus

Rocket Lab stock price today: RKLB slips after hours as Neutron tank test rupture keeps timeline in focus

Rocket Lab shares closed up 1.1% at $88.90 Friday, then slipped 0.4% after hours following news of a Stage 1 tank rupture during Neutron rocket testing. The company is assessing possible schedule impacts. Earlier, Rocket Lab completed its first Electron launch of 2026 and plans another mission next week. Director Jon Olson sold 15,205 shares on Jan. 20 under a pre-arranged plan.
24 January 2026
···
Rocket Lab stock rebounds as Neutron test rupture hangs over 2026 debut

Rocket Lab stock rebounds as Neutron test rupture hangs over 2026 debut

Rocket Lab shares rose 3.1% to $90.72 by late Friday morning after a Stage 1 tank rupture during Neutron rocket testing raised concerns about launch delays. The company is reviewing test data to assess impacts on its schedule, with an update expected during its February earnings call. Director Jon A. Olson sold 15,205 shares on Jan. 20, retaining 345,630. Rocket Lab completed its 80th Electron launch this week.
23 January 2026
····
Rocket Lab stock slides as analysts lift targets — what RKLB traders are watching next

Rocket Lab stock slides as analysts lift targets — what RKLB traders are watching next

Rocket Lab shares fell 3.9% to $92.60 by late morning Tuesday, tracking declines in the S&P 500 and Nasdaq. BofA doubled its price target to $120 while Goldman Sachs raised its target to $69 but kept a neutral rating. Shares traded between $91.60 and $98.27, below their 52-week high. Rocket Lab’s next earnings report is expected after the close on Feb. 26.
20 January 2026
··
Rocket Lab stock slips in premarket after Goldman target hike as tariff jitters hit futures

Rocket Lab stock slips in premarket after Goldman target hike as tariff jitters hit futures

Rocket Lab shares fell 3.6% to $92.86 in early Tuesday trading after closing near record highs Friday. Goldman Sachs raised its price target to $69 but kept a Neutral rating, citing momentum in defense tech. S&P 500 and Nasdaq futures dropped on tariff concerns, weighing on sentiment. Investors await Rocket Lab’s next earnings report on February 26.
20 January 2026
··
Rocket Lab stock jumps after Morgan Stanley upgrade, new $105 target puts RKLB back in play

Rocket Lab stock jumps after Morgan Stanley upgrade, new $105 target puts RKLB back in play

Rocket Lab USA shares rose 6.1% to $96.30 Friday after Morgan Stanley upgraded the stock to Overweight and raised its price target to $105. The stock gained another 0.5% in after-hours trading. Director Merline Saintil sold 108,500 shares this week at prices between $86.58 and $90, according to SEC filings. Rocket Lab’s next earnings report is expected around Feb. 26.
16 January 2026
··
Rocket Lab stock jumps on Morgan Stanley upgrade as KeyBanc warns the rally may be “priced in”

Rocket Lab stock jumps on Morgan Stanley upgrade as KeyBanc warns the rally may be “priced in”

Morgan Stanley upgraded Rocket Lab to “overweight” and raised its price target from $67 to $105, sending shares up 6% to $96 on Friday. KeyBanc downgraded the stock to “sector weight,” citing valuation concerns and uncertainty over the Neutron rocket’s launch timeline. Investors are watching Neutron’s inaugural flight as Rocket Lab’s market cap hit $48 billion.
16 January 2026
··
Rocket Lab stock jumps 6% as Cantor repeats bullish call; RKLB slips after hours

Rocket Lab stock jumps 6% as Cantor repeats bullish call; RKLB slips after hours

Rocket Lab shares closed up 6% at $91.80 Wednesday after Cantor Fitzgerald reaffirmed its “Overweight” rating, citing progress on the Neutron rocket. The stock slipped 0.6% after hours. Rocket Lab recently won an $816 million U.S. defense contract to build 18 missile-warning satellites, part of a $3.5 billion government initiative. The company reported record Q3 revenue of $155 million.
15 January 2026
···
Rocket Lab stock hovers near highs after Baird lifts RKLB target to $100 — what’s next

Rocket Lab stock hovers near highs after Baird lifts RKLB target to $100 — what’s next

Rocket Lab shares rose 0.1% to $87.98 by midday Tuesday after Baird raised its price target to $100, citing a recent $816 million U.S. defense satellite contract. The stock traded on heavy volume as investors focused on execution risks and the company’s upcoming earnings. Rocket Lab’s revenue surged 52% over the past year, but it remains unprofitable.
13 January 2026
··
Rocket Lab stock jumps today despite $103 million CFO sale filing: what RKLB traders watch next

Rocket Lab stock jumps today despite $103 million CFO sale filing: what RKLB traders watch next

Rocket Lab shares climbed 4.6% to $86.87 Friday morning after SEC filings showed CFO Adam Spice sold $103.1 million in stock and COO Frank Klein sold $7.3 million, both under preset 10b5-1 plans. Shares had dropped 1.2% Thursday following the insider sales. Investors are watching for the next earnings update and any changes to the Neutron rocket timetable.
9 January 2026
··
1 2 3 4 5

Stock Market Today

  • BIO-key Receives Nasdaq Notice for Delayed 10-Q Filing
    June 10, 2026, 5:45 PM EDT. BIO-key International, Inc. (OTC: BKYI) received a non-compliance notice from Nasdaq for failing to file its Quarterly Report on Form 10-Q for Q1 2026 on time as required by Nasdaq Listing Rule 5250(c)(1). Nasdaq's notification states the company's delay could affect its continued listing on the Nasdaq Capital Market pending a Hearing Panel determination. BIO-key specializes in biometric authentication and identity access management (IAM) technologies. The company serves over 40 million users with its cloud-hosted and on-premise PortalGuard IAM solution, supporting secure, multi-factor authentication options including passwordless methods. This regulatory development adds pressure on BIO-key to meet reporting requirements amid its efforts to secure market confidence.

Latest articles

Joby Aviation Shares Slip After CFO Files to Sell Stock

Joby Aviation Shares Slip After CFO Files to Sell Stock

10 June 2026
Joby Aviation fell 4.47% to $8.86 after CFO Rodrigo Brumana disclosed selling 78,489 shares under a prearranged 10b5-1 plan, with no new certification or commercial-launch updates, leaving investors focused on regulatory progress and cash burn as the key catalysts for the stock.
YY Group Shares Spike as Humanoid Robot Plans Unveiled

YY Group Shares Spike as Humanoid Robot Plans Unveiled

10 June 2026
YY Group Holding shares surged to $0.165 on heavy volume after announcing a commercial humanoid-robotics initiative using Unitree G1 robots and facility-management data, reframing the company as a robotics-and-AI data play; the rally comes despite 2025 net loss, dilution risk from a relaunched at-the-market share-sale program, and no disclosed robot-related revenue or contracts.
Snap Inc. Targets Health Ad Dollars With New Snapchat Study as Pressure Builds

Snap Shares Drop Again With Tech Names Under Pressure

10 June 2026
Snap Inc. shares slid 4% to $5.38, extending a three-day losing streak and deepening doubts about its turnaround despite improved cash flow and cost cuts, as investors await CEO Evan Spiegel’s June 16 AWE keynote and weigh weak ad growth, falling eCPMs, and ongoing macro and regulatory risks.
Go toTop